Trial Profile
A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor AS703026 Given Orally to Subjects With Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Pimasertib (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Mesothelioma; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Merck KGaA
- 19 Nov 2020 Results (n=89) assessing efficacy, safety, and pharmacodynamics of pimasertib at pharmacologically active doses in patients with melanoma, published in the Targeted Oncology
- 10 Nov 2020 After determination of MTD and/or MAD for Regimen1/Regimen2, and critical evaluation of need for a washout period between doses based on safety, PK and PD outcomes, clinical trial protocol was amended to allow for testing of continuous qd and continuous bid dosing in patients with Melanoma (since preliminary evidence of antitumor activity had been observed in melanoma patients).
- 10 Nov 2020 Results published in the Targeted Oncology